Repatha, a cholesterol-lowering injectable known generically as evolocumab, just became the first PCSK9 inhibitor proven to prevent heart attacks and strokes in people who have never had one. Results from the Phase 3 VESALIUS-CV trial, presented at the 2025 American Heart Association Scientific Sessions and published in the New England Journal of Medicine, showed that Repatha reduced the risk of a first major adverse cardiovascular event by 25 percent in high-risk adults with no prior cardiac history. For the millions of people walking around with dangerously high cholesterol or early-stage arterial disease who have been told they are “at risk” but haven’t yet suffered a cardiac event, this is a significant shift in what preventive medicine can offer. But Repatha is not the only drug changing the landscape of heart attack prevention.
The FDA approved colchicine — an old gout medication — as the first anti-inflammatory drug specifically indicated for cardiovascular risk reduction. A 2025 Johns Hopkins study revealed that nearly half of Americans eligible for statins aren’t taking them, a gap that costs tens of thousands of preventable deaths each year. And newer therapies like Eli Lilly’s lepodisiran and a novel use of N-acetyl cysteine discovered at Georgia Tech are pushing the boundaries of what we know about stopping heart attacks before they start. For readers of this site, the connection matters directly: cardiovascular health and brain health are deeply intertwined, and what protects the heart often protects cognition. This article walks through each of these developments in detail — what works, what’s still unproven, and what you should actually discuss with your doctor.
Table of Contents
- How Does Repatha Reduce Heart Attack Risk in Patients Who Have Never Had One?
- Colchicine and the Anti-Inflammatory Approach to Preventing First Heart Attacks
- The Statin Gap — Why Half of Eligible Americans Still Aren’t Protected
- Comparing the Options — Which Heart Attack Prevention Drug Makes Sense for Whom?
- Lp(a) and the Genetic Risk Factor No One Could Treat Until Now
- An Old Drug, a New Discovery — NAC and Blood Clot Prevention
- What These Developments Mean for Brain Health and Dementia Prevention
- Conclusion
- Frequently Asked Questions
How Does Repatha Reduce Heart Attack Risk in Patients Who Have Never Had One?
Repatha works by blocking a protein called PCSK9, which normally prevents the liver from clearing LDL cholesterol from the blood. When PCSK9 is inhibited, the liver pulls more LDL out of circulation, driving cholesterol levels far below what statins alone can achieve. The VESALIUS-CV trial enrolled over 12,000 adults aged 50 to 79 who had atherosclerotic cardiovascular disease or high-risk diabetes but had never experienced a heart attack or stroke. Over a median follow-up of roughly 4.5 years, patients receiving Repatha on top of standard therapy saw that 25 percent reduction in first major adverse cardiovascular events — a composite that includes heart attack, stroke, and cardiovascular death. What makes this trial particularly notable is that Repatha had already demonstrated benefit in secondary prevention, meaning after a patient has already suffered a cardiac event.
The VESALIUS-CV results make it the first and only PCSK9 inhibitor to show statistically significant benefit on both sides of that divide. That distinction matters because the medical community has long debated how aggressively to treat patients who are high-risk but event-free. Many clinicians have been cautious about prescribing expensive injectable therapies for people who feel perfectly healthy, and this data gives them something concrete to point to. However, access remains a real barrier — Repatha carries a significant price tag, and insurance coverage for primary prevention use is not guaranteed. Patients whose LDL remains stubbornly elevated despite maximum statin therapy are the most likely candidates, and a candid conversation with a cardiologist about cost, coverage, and realistic benefit is essential before starting.
Colchicine and the Anti-Inflammatory Approach to Preventing First Heart Attacks
On June 20, 2023, the FDA approved colchicine 0.5 mg tablets under the brand name Lodoco, making it the first anti-inflammatory drug ever approved specifically to reduce cardiovascular event risk. this was a conceptual breakthrough as much as a pharmaceutical one. For decades, heart disease prevention focused almost exclusively on cholesterol and blood pressure. The approval of colchicine validated a theory that had been building for years: that chronic, low-grade inflammation in the arteries is a driver of heart attacks and strokes independent of cholesterol levels. The evidence behind the approval is compelling. In the LoDoCo2 trial of 5,522 patients, those taking colchicine experienced the composite endpoint of cardiovascular death, heart attack, ischemic stroke, or coronary revascularization at a rate of 6.8 percent compared with 9.6 percent for placebo — a hazard ratio of 0.69. A 2025 meta-analysis expanded on these findings, reporting a 25 percent reduction in major adverse cardiovascular events overall, a 29 percent reduction in heart attacks, a 37 percent reduction in ischemic stroke, and a 33 percent reduction in urgent revascularization.
Per 1,000 individuals treated, that translates to approximately 9 heart attacks and 8 strokes prevented. However, colchicine is not without caveats. It can cause gastrointestinal side effects including diarrhea and nausea, which lead some patients to discontinue. It also interacts with several common medications, including certain statins and antibiotics, requiring careful dose management. Patients with severe kidney or liver impairment may not be candidates. And while the cardiovascular data is strong, colchicine has not yet been studied specifically in populations with concurrent dementia or significant cognitive decline — a gap that matters for readers here. If you or a loved one is managing both heart disease risk and cognitive concerns, the drug’s inflammation-lowering mechanism is theoretically promising for brain health, but that connection remains unproven in clinical trials.
The Statin Gap — Why Half of Eligible Americans Still Aren’t Protected
A 2025 study from Johns Hopkins Bloomberg School of Public Health laid bare one of the most frustrating problems in preventive cardiology: 47 percent of Americans who have never had a heart attack or stroke are eligible for statin therapy under current U.S. guidelines, but only 23 percent are actually taking one. That gap is not a minor statistical footnote. The researchers calculated that if statin use aligned with existing guidelines, the United States could prevent more than 39,000 deaths, approximately 100,000 non-fatal heart attacks, roughly 65,000 strokes, and about 88,000 bypass surgeries and artery-reopening procedures every year. Proper statin use could reduce the risk of major cardiovascular events by up to 27 percent across the eligible population. The reasons for this gap are varied and stubborn.
Some patients refuse statins because of concerns about side effects — particularly muscle pain, which occurs in a minority of users and can often be managed by switching to a different statin or adjusting the dose. Others distrust the medications because of misinformation circulated online. And a significant portion of the gap comes down to clinical inertia: doctors who don’t initiate the conversation, or who prescribe a statin but never follow up to ensure the patient is actually taking it. For people caring for aging family members, this is worth paying attention to. Cardiovascular events are a leading cause of sudden functional decline and hospitalization in older adults, and they can accelerate cognitive deterioration. A simple, inexpensive generic statin may be one of the most underused tools available for keeping an aging parent out of the emergency room.
Comparing the Options — Which Heart Attack Prevention Drug Makes Sense for Whom?
The landscape of heart attack prevention now includes cholesterol-lowering drugs at multiple intensity levels, an anti-inflammatory option, and emerging therapies targeting entirely different pathways. The right choice depends heavily on the individual patient’s risk profile, existing medications, and practical considerations like cost and administration. Statins remain the foundation — they are inexpensive, well-studied over decades, and available as a once-daily pill. For most people at moderate cardiovascular risk who have never had a heart attack, a statin is the appropriate first step. For patients whose LDL cholesterol remains above target despite maximum tolerated statin doses, adding Repatha can drive levels dramatically lower and, as the VESALIUS-CV trial showed, significantly reduce the risk of a first cardiovascular event.
The tradeoff is that Repatha requires injections every two weeks or once monthly, costs considerably more, and may require prior authorization battles with insurance. Colchicine occupies a different niche entirely — it addresses the inflammatory component of cardiovascular disease and can be used alongside cholesterol-lowering medications. At 0.5 mg once daily, it is a simple oral pill, and generic versions keep the cost modest. The key distinction is that colchicine works through a mechanism independent of cholesterol, so it may benefit patients whose residual cardiovascular risk persists even after their lipid numbers are well controlled. For a patient managing multiple health concerns alongside a caregiver, these practical differences — pill versus injection, cost, side effect profiles, insurance battles — are often what determine adherence far more than clinical trial data.
Lp(a) and the Genetic Risk Factor No One Could Treat Until Now
Lipoprotein(a), commonly written as Lp(a), is a genetically inherited cardiovascular risk factor that affects an estimated 20 to 30 percent of the global population. Unlike LDL cholesterol, Lp(a) levels are largely determined by your DNA rather than your diet or lifestyle, and until recently, no approved therapy could meaningfully lower them. Eli Lilly’s lepodisiran, a small interfering RNA drug, changed that picture dramatically in 2025. In the Phase 2 ALPACA trial — which enrolled 320 participants across 66 centers in 10 countries — lepodisiran reduced Lp(a) levels by up to 94 percent, with results published in the New England Journal of Medicine. No serious adverse events related to the treatment were reported.
The limitation, and it is an important one, is that lowering Lp(a) levels has not yet been proven to prevent actual heart attacks and strokes. The biological plausibility is strong, and genetic studies strongly suggest that lower Lp(a) levels confer cardiovascular protection, but a definitive outcomes trial is still underway. Eli Lilly’s Phase 3 ACCLAIM-Lp(a) program is currently enrolling patients to answer exactly this question. Until those results arrive — likely years from now — lepodisiran remains a promising but unproven therapy. If you’ve had your Lp(a) tested and it’s elevated, this is worth following closely, but it is not yet something your doctor can prescribe. For brain health specifically, elevated Lp(a) has been loosely associated with increased stroke risk, which in turn is a known accelerant of vascular dementia, making this research relevant beyond traditional cardiology.
An Old Drug, a New Discovery — NAC and Blood Clot Prevention
Researchers at Georgia Tech uncovered a surprising finding about N-acetyl cysteine, a cheap, widely available drug already used as an antioxidant supplement and for acetaminophen overdose treatment. In preclinical studies published in Arteriosclerosis, Thrombosis, and Vascular Biology in 2024, NAC completely prevented blood clot formation without increasing bleeding risk — a side effect that plagues every existing blood thinner on the market. The mechanism is distinct from current anticoagulants: rather than interfering with the clotting cascade directly, NAC targets von Willebrand factor, a protein central to how platelets stick together and form clots.
This matters because the bleeding risk associated with traditional blood thinners like warfarin and newer agents like apixaban is one of the most common reasons doctors hesitate to prescribe them, especially in older adults prone to falls. If NAC’s clot-preventing properties translate from preclinical models into human trials, it could be transformative for elderly patients managing both cardiovascular and fall risk simultaneously. That said, this research is still in early stages — no human clinical trials for this specific cardiovascular use have been completed, and it would be premature to start taking NAC supplements expecting heart attack prevention. The science is worth watching, not acting on yet.
What These Developments Mean for Brain Health and Dementia Prevention
Every advancement in heart attack prevention carries implications for the brain. Cardiovascular disease and dementia share overlapping risk factors — high cholesterol, chronic inflammation, blood clot disorders, and vascular damage all contribute to both conditions. Strokes, even small ones that go unnoticed, are a major driver of vascular dementia, and poor cardiovascular health in midlife is one of the strongest predictors of cognitive decline in later years. The drugs discussed in this article — statins, Repatha, colchicine, and emerging therapies targeting Lp(a) and clot formation — all address pathways that damage not just the coronary arteries but also the delicate vasculature of the brain.
This does not mean these drugs are dementia treatments. None have been approved for cognitive indications, and the research linking cardiovascular drug therapy directly to dementia risk reduction is still evolving. But for families already navigating a dementia diagnosis or trying to reduce risk in a parent with cardiovascular concerns, the message from 2025 cardiology research is clear: preventing a first heart attack or stroke is more achievable than ever, and doing so may help protect cognitive function as well. The conversation with a cardiologist or primary care physician about primary prevention is one of the most consequential medical discussions an aging adult can have.
Conclusion
The era of waiting for a heart attack before getting aggressive about prevention is ending. Repatha’s VESALIUS-CV trial proved that PCSK9 inhibitors can reduce first cardiovascular events by 25 percent in high-risk patients. Colchicine brought anti-inflammatory prevention into mainstream medicine. The staggering statin gap identified by Johns Hopkins researchers shows that tens of thousands of lives could be saved simply by using existing drugs as guidelines already recommend. And emerging therapies like lepodisiran and novel applications of NAC hint at a future where even genetically driven cardiovascular risk can be addressed.
For caregivers and anyone concerned about brain health in an aging loved one, these developments reinforce a principle that geriatricians have emphasized for years: protecting the heart is one of the most effective strategies for protecting the mind. If your parent, spouse, or patient has cardiovascular risk factors but has never been evaluated for preventive medication, 2025 has produced more reasons than ever to have that conversation with their doctor. The drugs exist. The evidence is strong. The gap between what medicine can do and what patients are actually receiving remains the biggest obstacle.
Frequently Asked Questions
Can Repatha be prescribed to someone who has never had a heart attack?
Yes. The VESALIUS-CV trial specifically studied adults who had never experienced a heart attack or stroke but had high cardiovascular risk due to atherosclerotic disease or high-risk diabetes. Repatha is now the first PCSK9 inhibitor with clinical evidence supporting use in this primary prevention population, though insurance coverage for this indication may vary.
Is colchicine safe to take long-term for heart disease prevention?
The LoDoCo2 trial followed patients for a median of 28.6 months with an acceptable safety profile. However, colchicine can cause gastrointestinal side effects and interacts with several medications. Patients with significant kidney or liver disease may not be good candidates. Long-term use should be monitored by a physician who is aware of all your other medications.
Why aren’t more people taking statins if the evidence is so strong?
The Johns Hopkins study identified multiple barriers: patient concerns about side effects, misinformation, and clinical inertia from healthcare providers who don’t initiate or follow up on statin therapy. Of the 47 percent of Americans eligible for statins, only 23 percent are currently taking them — a gap responsible for tens of thousands of preventable deaths annually.
Does lowering heart attack risk also reduce dementia risk?
Cardiovascular disease and dementia share many risk factors, and strokes are a direct cause of vascular dementia. While the heart attack prevention drugs discussed here have not been approved as dementia treatments, maintaining cardiovascular health — particularly avoiding strokes — is one of the most evidence-supported strategies for reducing cognitive decline risk.
What is Lp(a), and should I get tested for it?
Lipoprotein(a) is a genetically inherited cardiovascular risk factor that affects 20 to 30 percent of people. Unlike regular cholesterol, it doesn’t respond to diet or lifestyle changes. A simple blood test can measure it. If your levels are elevated, no approved therapy currently exists to lower them, but Eli Lilly’s lepodisiran showed up to 94 percent reduction in Phase 2 trials and is now being studied in a Phase 3 program.
Is NAC something I should start taking to prevent blood clots?
Not yet. The Georgia Tech research on NAC and clot prevention is still in preclinical stages — it has shown remarkable results in laboratory studies but has not been tested in human cardiovascular trials. Taking NAC supplements for heart attack prevention would be premature. Follow the research, but don’t act on it until human clinical data is available.
